CUMYL-CBMINACA
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Graeme Bartlett (talk | contribs) at 22:11, 7 August 2020 (inchi calculated from SMILES). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:11, 7 August 2020 by Graeme Bartlett (talk | contribs) (inchi calculated from SMILES)
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020.[1]
See also
References
- ^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Chem-molar-mass both hardcoded and calculated
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- All stub articles